Citations 230
Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).
Bernath, Albert M., Northfelt, Donald W. , Hou, Xiaonan , Tenner, Kathleen , Tienchaiananda, Piyawan , Flickinger, Lynn M. , Chen, Beiyun, Chen, Helen X., Lingle, Wilma L., Pellegrino, Christine, Sponzo, Robert W., Reinholz, Monica M., Perez, Edith A. , Haluska, Paul , Ballman, Karla V. , Dueck, Amylou C. , Linden, Hannah M. , Goetz, Matthew P.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 632-632
Genes associated with serum estrone, estrone conjugates, and androstenedione concentrations in postmenopausal women with estrogen receptor-positive breast cancer.
Dudenkov, Tanda M., Buzdar, Aman U. , Kubo, Michiaki , Batzler, Anthony , Jenkins, Gregory D. , Pietrzak, Tracy L., Northfelt, Donald W. , Perez, Edith A. , Williard, Clark, Nakamura, Yusuke , Wang, Liewei , Weinshilboum, Richard M. , Ingle, James N. , Robson, Mark E. , Carlson, Erin E. , Fridley, Brooke L. , Goetz, Matthew P. , Kalari, Krishna R. , Weinshilboum, Richard M.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 593-593
Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.
Perez, Edith A. , Thompson, E. Aubrey , Anderson, S. Keith , Asmann, Yan W. , Eckel‐Passow, Jeanette E. , Tenner, Kathleen , Jen, Jin , Fan, Jian‐Bing , Geiger, Xochiquetzal J., McCullough, Ann E. , Chen, Beiyun, Zschunke, Michael A., Jenkins, Robert B. , Reinholz, Monica M., Kalari, Krishna R. , Dueck, Amylou C. , Sledge, George W. , Winer, Eric P. , Gralow, Julie R. , Ballman, Karla V.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 509-509
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-posi
Piccart, Martine , Holmes, Andrew , Baselga, José , Viale, Giuseppe , Zujewski, Jo Anne , Goldhirsch, Aron, Jackisch, Christian , Láng, István, Smith, Ian E., Boyle, Frances , Gelber, Richard D. , Perez, Edith A. , Azambuja, Evandro de , Dueck, Amylou C. , Zujewski, Jo Anne , Santillana, Sergio, Pritchard, Kathleen I. , Wolff, Antonio C. , Untch, Michael , Xu, Binghe , Gómez, Henry
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA4-LBA4
Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT a
Pagani, Olivia , Regan, Meredith M. , Walley, Barbara , Láng, István, Burstein, Harold J. , Perez, Edith A. , Ciruelos, Eva, Martino, Silvana, Coates, Alan S. , Gelber, Richard D. , Goldhirsch, Aron, Group, SOFT and TEXT Investigators and International Breast Cancer Study, Fleming, Gini F. , Colleoni, Marco , Gómez, Henry , Tondini, Carlo Alberto , Stearns, Vered , Bonnefoi, Hervé , Geyer, Charles E. , Rabaglio, Manuela , Francis, Prudence A. , Group, SOFT and TEXT Investigators and International Breast Cancer Study
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA1-LBA1
Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Chapman, Judy‐Anne W., Burnell, Margot J., Levine, Mark N. , Whelan, Timothy J. , Albain, Kathy S. , Perez, Edith A. , Virk, Shakeel , O’Brien, Patti, Shepherd, Lois E. , Gelmon, Karen A. , Liu, Shuzhen , Pritchard, Kathleen I. , Rugo, Hope S. , Nielsen, Torsten O.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 11019-11019
Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.
Advani, Pooja , Dockter, Travis , Colón‐Otero, Gerardo , Perez, Edith A. , Ballman, Karla V.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 603-603
Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer.
Spector, Neil L., Mano, Max S. , Canon, Jean-Luc, Gómez, Henry , El‐Hariry, Iman , Vukovic, Vojislav, Sheldon, Emily H, Perez, Edith A. , Cameron, David , Cortés, Javier , Canon, Jean-Luc Re , Hickish, Tamas , Vahdat, Linda T. , Kim, Sung-Bae , Awada, Ahmad
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS665-TPS665
Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤ 2cm: A meta-analysis of the randomized trastuzumab trials.
O’Sullivan, Ciara C. , Bradbury, Ian , Perez, Edith A. , Rastogi, Priya , Spielmann, M., Costantino, Joseph P., Zardavas, Dimitrios, Piccart, Martine , Zujewski, JoAnne, Holmes, Eileen , Gelber, Richard D. , Azambuja, Evandro de , Joensuu, Heikki , Ballman, Karla V. , Delaloge, Suzette , Zujewski, Jo Anne
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 508-508
Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC).
Chapman, Judy‐Anne W., Burnell, Margot J., Levine, Mark N. , O’Brien, Patti, Han, Lei , Albain, Kathy S. , Perez, Edith A. , Vandenberg, Theodore A. , Chalchal, Haji , Sawhney, Ravinder, Shepherd, Lois E. , Lohmann, Ana Elisa , Tsvetkova, Elena V. , Pritchard, Kathleen I. , Gelmon, Karen A. , Rugo, Hope S. , Goodwin, Pamela J.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 504-504